PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Phenelzine sulfate - Depression

PAD Profile : Phenelzine sulfate - Depression

Keywords :
MAOIs, monoamine oxidase inhibitors, depressive illness, antidepressants
Brand Names Include :
Nardil

Traffic Light Status

Status 1 of 1.

Status :
Blue
Important
Formulations :
  • Tablets
Important Information :
Initiation and stabilisation by specialist for a minimum of 6 months before transfer of prescribing to primary care.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date
Information
01 October 2023

Committee Recommendations

Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartland Integrated Care System Area Prescribing Committee have agreed a BLUE (with information sheet) traffic light status for:

·         Phenelzine

·         Isocarboxacid

·         Moclobemide

·         Tranylcypromine

Specialists will initiate and prescribe a minimum of 6 months or until the patient is stable, whichever is longer, prior to transfer of care

05 October 2022
Primary Care Medicines Optimisation Clinical reference Group (PCMOCRG)

Licensed phenelzine 15mg tablets have now returned to the market following a period of supply problems, during which, the only available phenelzine preparations were unlicensed tablets and capsules.

However, there is currently no Traffic Light Status within Surrey Heartlands for Monoamine-Oxidase Inhibitors (MAOIs). 

It is recommended that the prescribing remains with the specialist until discussions have been held by the Area Prescribing Committee.

Please refer to the document below for further context

Associated BNF Codes

04. Central Nervous System
04.03.02. Monoamine-oxidase inhibitors (maois)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More